Guizhou Bailing Group Pharmaceutical Co., Ltd. Stock price

Equities

002424

CNE100000PY3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
7.75 CNY +1.44% Intraday chart for Guizhou Bailing Group Pharmaceutical Co., Ltd. -1.27% -4.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 4.47B 622M Sales 2024 * 5.43B 755M Capitalization 10.74B 1.49B
Net income 2023 * 311M 43.21M Net income 2024 * 460M 63.91M EV / Sales 2023 * 2.4 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.98 x
P/E ratio 2023 *
35.2 x
P/E ratio 2024 *
23.5 x
Employees 6,138
Yield 2023 *
-
Yield 2024 *
-
Free-Float 67.64%
More Fundamentals * Assessed data
Dynamic Chart
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug MT
China steel association says EU carbon tax a new trade barrier, calls for more talks RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China’s Steel Consumption Falls 1.5% in January-September Period MT
China steel supply needs adjusting, industry official says RE
EU to launch first phase of world-first CO2 border tax RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 9, 2023 has closed with 12,096,900 shares, representing 0.87% for CNY 100.01 million. CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Announces Management Appointments CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
More news
1 day+1.44%
1 week-1.27%
1 month+6.90%
3 months-6.40%
6 months-1.40%
Current year-4.44%
More quotes
1 week
7.56
Extreme 7.56
8.03
1 month
6.56
Extreme 6.56
8.23
Current year
6.56
Extreme 6.56
8.35
1 year
6.56
Extreme 6.56
9.22
3 years
5.68
Extreme 5.68
11.97
5 years
5.68
Extreme 5.68
14.20
10 years
5.68
Extreme 5.68
37.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 07-12-24
Director of Finance/CFO 39 20-12-28
Director/Board Member 40 14-01-26
Members of the board TitleAgeSince
Chairman 63 07-12-24
Director/Board Member 56 07-12-24
Chief Executive Officer 54 07-12-24
More insiders
Date Price Change Volume
24-02-29 7.75 +1.44% 23,267,690
24-02-28 7.64 -2.92% 37,408,890
24-02-27 7.87 +0.77% 22,574,940
24-02-26 7.81 -0.38% 22,245,490
24-02-23 7.84 -0.13% 25,693,570

End-of-day quote Shenzhen S.E., February 28, 2024

More quotes
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.75
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Guizhou Bailing Group Pharmaceutical Co., Ltd. - Shenzhen S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW